As the UK’s leading consumer cannabinoid biotechnology company, we are excited to announce the launch of our dedicated cannabis research facility to study the potential medical applications of the cannabis plant.

Over 2 years ago the UK saw the release of the MediPen® Cannabinoid Vaporizer, a legal handheld device now used by thousands and widely responsible for reshaping public opinion on cannabis. By working with industry leading scientists and product designers, MediPen® has quickly become a world renowned brand with more publicly available positive user feedback than any single cannabis product in its sector.

As a firm believer in enhancing research into medicinal cannabis, we are committed to reinvesting into further developing our R&D network, and are pleased to announce the public launch of the MediPen® Cannabis Research Facility.

This marks the beginning of a strenuous course of clinical trials and research into the medicinal applications of several cannabis constituents, with the goal of developing a portfolio of licensed cannabinoid based medicines in the coming years.

In particular, we are keen to explore the applications of key phytocannabinoids such as Δ9-tetrahydrocannabinol (THC) for use in cancer patients, with the aim of not only minimising the negative impact of existing chemotherapy based treatments such as nausea and vomiting through its antiemetic properties, but also attempting to suppress metastasis through inhibiting the proliferation of cancer cells.

There is a large amount of existing scientific and anecdotal evidence supporting this mission which we are extremely keen to study and reaffirm through a series of placebo controlled double blind scientific trials. Something which due to current prohibition laws and difficulty obtaining licensing has been almost impossible until now.

With the launch of our dedicated cannabis research facility, we are excited to further propel the UK to the forefront of global cannabinoid research and innovation.

The flagship MediPen® Cannabis Research Facility will also host a platform in which support will be provided to founders of other cannabis based innovations who are encouraged to take advantage of their established R&D network, state of the art in-house testing facilities as well as on board business and legal advice.

At MediPen®, our primary objective is to propel the United Kingdom to the global forefront of cannabis research and development. A mission fuelled by rigorous scientific research, backed by our thousands of passionate supporters and a thirst for developing world-renowned formulations using natural extracts sourced from the cannabis genus. We’ve been extremely successful over the past few years in opening the eyes of millions of people across the world to the positive attributes of the cannabis plant - a plant which has been subject to a storm of misinformation and negative connotations until now.

A New Chapter In The Cannabis Legalisation Campaign

Prior to our inception, very few members of the general public had ever heard of the plant’s non-psychoactive constituents such as Cannabidiol (CBD), Cannabidivarin (CBD) and Cannabigerol (CBG). Through working with industry leading experts and dedicating our lives to building a reputable organisation committed to exploring the potential applications of these key extracts, collectively known as phytocannabinoids, we’ve been able to to completely eradicate the damaging preconceptions surrounding cannabis and demonstrate first hand that there is far more to the plant than its stereotypical recreational ties.

As the first UK company to receive public written confirmation from the Home Office that there are no legal restrictions surrounding the use, sale, import or possession of our active ingredients, we have finally been able to ignite the cannabis revolution nationwide. 

MediPen® Cannabinoid Vaporizer (CBD, CBDV, CBG)

Following the success of the launch of our flagship product, the MediPen® Cannabinoid Vaporizer, the UK’s legal cannabinoid industry was born. As a result of our exemplary user feedback we’ve been able to achieve extremely positive coverage surrounding the use of non-psychotropic cannabinoids, and in early 2015 our product began to receive vast media recognition across the globe. Since then, the UK CBD industry has come a very long way with thousands of users discovering products such as CBD Oil on a daily basis.

Our key focus for the industry is to provide easy access to world-class cannabinoid extracts and provide the general public with a vast compendium of resources and access to a collection of peer reviewed scientific studies detailing the plant’s myriad of potential applications. Our passion for helping people and constantly improving our premium product range has even resulted in a network of thousands of our active users coming together and helping each other get the most out of their MediPen® experience.

The Future Of The UK Cannabinoid Market

MediPen® Is Committed To Campaigning For Safe & Legal Access To Medicinal Cannabis Across The UK